Scarica l'app Stockscreener
5.10
6.59%
-0.36
Dopo l'orario di chiusura:
5.15
0.05
+0.98%
Precedente Chiudi:
$5.46
Aprire:
$5.43
Volume 24 ore:
430.78K
Relative Volume:
0.69
Capitalizzazione di mercato:
$256.89M
Reddito:
$230.47M
Utile/perdita netta:
$30.28M
Rapporto P/E:
8.3607
EPS:
0.61
Flusso di cassa netto:
$38.86M
1 W Prestazione:
-2.49%
1M Prestazione:
-3.95%
6M Prestazione:
+60.38%
1 anno Prestazione:
+78.95%
Intervallo 1D:
$5.10
$5.43
Intervallo di 1 settimana:
$5.10
$5.6136
Portata 52W:
$2.32
$6.07
Puma Biotechnology Inc Stock (PBYI) Company Profile
Nome
Puma Biotechnology Inc
Settore
Industria
Telefono
(424) 248-6500
Indirizzo
10880 WILSHIRE BLVD., LOS ANGELES, CA
Confronta PBYI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PBYI
Puma Biotechnology Inc
|
5.10 | 275.02M | 230.47M | 30.28M | 38.86M | 0.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Puma Biotechnology Inc Stock (PBYI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-09-28 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-06-25 | Ripresa | BofA/Merrill | Underperform |
| 2019-10-08 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-10 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2019-05-10 | Downgrade | Citigroup | Buy → Neutral |
| 2019-01-17 | Iniziato | Leerink Partners | Mkt Perform |
| 2019-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2018-11-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-11-02 | Downgrade | BofA/Merrill | Buy → Underperform |
| 2018-11-02 | Downgrade | JP Morgan | Neutral → Underweight |
| 2018-10-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-17 | Iniziato | Goldman | Sell |
| 2018-05-11 | Reiterato | Stifel | Buy |
| 2017-11-10 | Reiterato | Citigroup | Buy |
| 2017-11-10 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-10-02 | Reiterato | Stifel | Buy |
| 2017-09-11 | Reiterato | Credit Suisse | Outperform |
| 2017-07-10 | Ripresa | Leerink Partners | Outperform |
| 2017-06-06 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-05-25 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2017-03-02 | Reiterato | RBC Capital Mkts | Sector Perform |
Mostra tutto
Puma Biotechnology Inc Borsa (PBYI) Ultime notizie
How strong is Puma Biotechnology Inc. stock revenue growth2025 Short Interest & Long-Term Safe Investment Plans - newser.com
Using Ichimoku Cloud for Puma Biotechnology Inc. technicalsPortfolio Return Report & Technical Confirmation Trade Alerts - newser.com
Can Puma Biotechnology Inc. stock withstand economic slowdown2025 Historical Comparison & AI Enhanced Trading Signals - newser.com
How institutional buying supports Puma Biotechnology Inc. stock2025 Price Targets & Safe Entry Point Identification - newser.com
Is Puma Biotechnology Inc. reversing from oversold territoryJuly 2025 EndofMonth & Accurate Entry and Exit Point Alerts - newser.com
Using R and stats models for Puma Biotechnology Inc. forecasting2025 Top Decliners & Community Consensus Trade Signals - newser.com
Global Desmoid Tumors Market Report 2025: Regional and Country-Level Analysis & Forecast to 2035 Featuring SpringWorks Therapeutics, Ayala Pharma, Puma Biotechnology, BMS, Eli Lilly, Ipsen, Deciphera Pharma - Yahoo Finance
Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday - MarketBeat
Will Puma Biotechnology Inc. stock remain a Wall Street favorite - fcp.pa.gov.br
Puma Biotechnology (NASDAQ:PBYI) Downgraded to Hold (C+) Rating by Weiss Ratings - MarketBeat
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2025 Financial Results - BioSpace
Puma Biotechnology to Host Conference Call to Discuss Third Quarter Financial Results - The AI Journal
Puma Biotechnology targets $192M-$198M NERLYNX revenue for 2025 amid strategic efforts - MSN
Why Puma Biotechnology Inc. is moving todayJuly 2025 Earnings & AI Enhanced Market Trend Forecasts - newser.com
Is Puma Biotechnology Inc. stock a safe investment in uncertain marketsProduct Launch & Short-Term Trading Opportunity Alerts - newser.com
Chart overlay techniques for tracking Puma Biotechnology Inc.Fed Meeting & Smart Money Movement Alerts - newser.com
Exit strategy if you’re trapped in Puma Biotechnology Inc.Bear Alert & Low Drawdown Momentum Trade Ideas - newser.com
Relative strength of Puma Biotechnology Inc. in sector analysisQuarterly Portfolio Report & Safe Capital Growth Tips - newser.com
Is now a turning point for Puma Biotechnology Inc.July 2025 Technicals & Verified Entry Point Signals - newser.com
Multi asset correlation models including Puma Biotechnology Inc.July 2025 Pullbacks & Safe Entry Point Identification - newser.com
Puma Biotechnology Inc Azioni (PBYI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.62%
0.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):